Aminoguanidine Prevents the Decreased Myocardial Compliance Produced by Streptozotocin-Induced Diabetes Mellitus in Rats
- 15 May 1996
- journal article
- Published by Wolters Kluwer Health in Circulation
- Vol. 93 (10) , 1905-1912
- https://doi.org/10.1161/01.cir.93.10.1905
Abstract
Background A decreased cardiac compliance is a major feature of the cardiomyopathy of diabetes mellitus. Either an increase in the resistance afterload to the LV or an increase in collagen cross-linking induced by the formation of advanced glycosylation end products (AGEs) of collagen may be responsible for the stiff myocardium. To evaluate these hypotheses, we examined the effect of captopril, an afterload-reducing agent, and aminoguanidine, a nucleophilic hydrazine that prevents the accumulation of collagen AGEs, on left ventricular end-diastolic (LVED) compliance after 4 months of streptozotocin (0.26 mmol/kg)–induced diabetes mellitus in rats. Methods and Results Diabetes mellitus produced a decrease in LV chamber compliance as a result of an increased myocardial stiffness (slope of the linearized LVED stress–LVED strain relation [unitless]: diabetes mellitus, 47±4; control, 27±3; P<.001) and an increase in blood pressure as a result of an elevated vascular resistance. LV end-systolic elastance was unaltered by diabetes mellitus. The stiff myocardium was not associated with changes in the myocardial collagen volume fraction or total hydroxyproline concentration but was associated with an increased myocardial collagen fluorescence (fluorescence units/μg hydroxyproline) (diabetes mellitus, 11±1.1; control, 6.6±0.7; P<.01). Captopril therapy (0.22 mmol ·kg−1·d−1), despite producing a decrease in blood pressure through alterations in vascular resistance, failed to decrease myocardial stiffness in rats with diabetes mellitus. Alternatively, administration of aminoguanidine (7.35 mmol·kg−1·d−1) prevented both the enhanced myocardial collagen fluorescence (7.1±1.2) and the increased slope of the linearized LVED stress–LVED strain relation (29±2) but did not change markers of blood glucose control. Conclusions These results demonstrate that diabetes mellitus can produce a stiff myocardium before the development of myocardial fibrosis. The stiff myocardium in the early stages of the development of the cardiomyopathy of diabetes mellitus is not a consequence of an increase in ventricular resistance afterload and in these circumstances is associated with the formation of collagen AGEs.Keywords
This publication has 18 references indexed in Scilit:
- Nuclear-magnetic-resonance characterization of doped SiO2 films used in integrated circuitsJournal of Applied Physics, 1995
- Hydrochlorothiazide improves ventricular compliance and thus performance without reducing hypertrophy in renal artery stenosis in rats.Hypertension, 1993
- Glycation Products and the Pathogenesis of Diabetic ComplicationsDiabetes Care, 1992
- Correlation between histopathological changes and mechanical dysfunction in diabetic rat heartsDiabetes Research and Clinical Practice, 1991
- Abnormal cardiac function in the streptozotocin-diabetic rat. Changes in active and passive properties of the left ventricle.Journal of Clinical Investigation, 1990
- Evidence against the involvement of nonenzymatic glycosylation in diabetic cardiomyopathyMetabolism, 1990
- Aminoguanidine Prevents Diabetes-Induced Arterial Wall Protein Cross-LinkingScience, 1986
- Coronary blood flow in genetic cardiac hypertrophyThe American Journal of Cardiology, 1984
- Assessment of passive elastic stiffness of cardiac muscle: Mathematical concepts, physiologic and clinical considerations, directions of future researchProgress in Cardiovascular Diseases, 1976
- Determination of hydroxyprolineClinica Chimica Acta; International Journal of Clinical Chemistry, 1967